[1]叶益舟,凌铭培,余 娟,等.罗沙司他与促红素在血液透析患者肾性贫血中的效果比较[J].医学信息,2024,37(16):52.[doi:10.3969/j.issn.1006-1959.2024.16.010]
 YE Yi-zhou,LING Ming-pei,YU Juan,et al.Comparison of the Effects of Rosalrestat Erythropoietin on Renal Anemia in Hemodialysis Patients[J].Journal of Medical Information,2024,37(16):52.[doi:10.3969/j.issn.1006-1959.2024.16.010]
点击复制

罗沙司他与促红素在血液透析患者肾性贫血中的效果比较()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年16期
页码:
52
栏目:
论著
出版日期:
2024-08-15

文章信息/Info

Title:
Comparison of the Effects of Rosalrestat Erythropoietin on Renal Anemia in Hemodialysis Patients
文章编号:
1006-1959(2024)16-0052-04
作者:
叶益舟凌铭培余 娟李小生
龙南市第一人民医院肾内科,江西 龙南 341700
Author(s):
YE Yi-zhouLING Ming-peiYU JuanLI Xiao-sheng
Department of Nephrology,Longnan First People’s Hospital,Longnan 341700,Jiangxi,China
关键词:
罗沙司他促红素血液透析肾性贫血铁代谢
Keywords:
RosalrestatErythropoietinHemodialysisRenalanemiaIron metabolism
分类号:
R692
DOI:
10.3969/j.issn.1006-1959.2024.16.010
文献标志码:
A
摘要:
目的 比较罗沙司他与促红素治疗血液透析患者肾性贫血的临床疗效。方法 选取2022年1月-12月龙南市第一人民医院收治的78例血液透析合并肾性贫血患者临床资料,根据治疗方式不同分为对照组、观察组,每组39例。对照组给予促红素治疗,观察组给予罗沙司他治疗。比较两组铁代谢指标[铁调素(Hepc)、转铁蛋白(TRF)、转铁蛋白饱和度(TSAT)、血清铁蛋白(SF)]、贫血指标[红细胞比容(Hct)、血红蛋白(Hb)与红细胞计数(RBC)]以及不良反应(心力衰竭、头疼、恶心、腹泻)发生情况。结果 观察组治疗后Hepc水平低于对照组,TRF、TSAT、SF水平均高于对照组,差异有统计学意义(P<0.05);观察组治疗后Hct、Hb、RBC水平均高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率(5.13%)低于对照组(28.21%),差异有统计学意义(P<0.05)。结论 相较于促红素治疗,罗沙司他治疗血液透析患者肾性贫血的疗效更加理想,利于改善机体铁代谢与贫血状况,且用药安全性高。
Abstract:
Objective To compare the clinical efficacy of rosalrestat and erythropoietin in the treatment of renal anemia in hemodialysis patients.Methods The clinical data of 78 hemodialysis patients with renal anemia admitted to Longnan First People’s Hospital from January to December 2022 were selected and divided into control group and observation group according to different treatment methods, with 39 patients in each group. The control group was treated with erythropoietin, and the observation group was treated with rosalrestat. The iron metabolism indexes [hepcidin (Hepc), transferrin (TRF), transferrin saturation (TSAT), serum ferritin (SF)], anemia indexes [hematocrit (Hct), hemoglobin (Hb) and red blood cell count (RBC)] and adverse reactions (heart failure, headache, nausea, diarrhea) were compared between the two groups.Results After treatment, the level of Hepc in the observation group was lower than that in the control group, and the levels of TRF, TSAT and SF were higher than those in the control group, the differences were statistically significant (P<0.05). After treatment, the levels of Hct, Hb and RBC in the observation group were higher than those in the control group, and the differences were statistically significant(P<0.05). The incidence of adverse reactions in the observation group (5.13%) was lower than that in the control group (28.21%), and the difference was statistically significant (P<0.05).Conclusion Compared with erythropoietin, rosalrestat is more effective in the treatment of renal anemia in hemodialysis patients, which is beneficial to improve iron metabolism and anemia, and has high safety.

参考文献/References:

[1]黄思梅,胡煜琳.罗沙司他与重组人促红素联合静脉铁剂治疗铁达标的维持性血液透析患者肾性贫血的疗效比较[J].中国临床医生杂志,2023,51(5):574-577.[2]沈志伟,金秀名,陈军童.罗沙司他联合重组人促红素治疗尿毒症肾性贫血维持性血液透析患者的效果分析[J].医学理论与实践,2023,36(2):262-264.[3]刘紫秋,杨婷,王路路,等.口服铁剂联合重组人促红素注射液与口服铁剂联合罗沙司他对血液透析患者血红蛋白和铁蛋白影响的对比观察[J].临床和实验医学杂志,2023,22(2):153-157.[4]王莉丽,侯儆,杨蔓玲,等.罗沙司他联合琥珀酸亚铁治疗维持性血液透析肾性贫血患者的疗效分析[J].中国医刊,2023,58(8):844-848.[5]王莉丽,杨蔓玲,侯儆,等.基于促红细胞生成素、白细胞介素-6水平及血红蛋白治疗前后最大差值变化评价罗沙司他在血液透析肾性贫血患者的应用疗效与安全性[J].临床肾脏病杂志,2023,23(5):357-362.[6]洪义芬,王自强,彭红伟,等.罗沙司他对比促红细胞生成素治疗老年血液透析合并肾性贫血的疗效及对心血管指标的影响[J].中国老年学杂志,2023,43(12):2903-2906.[7]袁新科,周璐婷,田俊玮,等.罗沙司他胶囊治疗艾滋病维持性血液透析患者的临床研究[J].中国临床药理学杂志,2023,39(11):1543-1546.[8]汪启龙.罗沙司他联合生血宁片对血液透析肾性贫血患者的影响[J].医学理论与实践,2023,36(7):1160-1163.[9]宗慧敏,王栖栖,朱江,等.罗沙司他对血液透析合并肾性贫血患者的治疗效果及影响因素分析[J].国际泌尿系统杂志,2023,43(2):308-312.[10]林宝丽,金利思,陈智.罗沙司他胶囊治疗慢性肾衰竭维持性血液透析肾性贫血患者的效果[J].中国医药导报,2023,20(1):111-114.[11]张蓬杰,荀利如,丁通,等.应用罗沙司他与重组人促红素治疗的初始血液透析肾性贫血患者的临床疗效及安全性分析[J].临床肾脏病杂志,2022,22(11):917-923.[12]钟小桂.重组人促红素注射液与罗沙司他胶囊治疗维持性血液透析肾性贫血的效果及对血清Hb、SF、CRP的影响[J].吉林医学,2022,43(8):2153-2154.[13]张游,霍洁,邹欢,等.罗沙司他胶囊对比重组人促红素注射液治疗维持性血液透析肾性贫血的有效性及安全性[J].国际泌尿系统杂志,2022,42(3):394-397.[14]杨亮.罗沙司他治疗维持性血液透析患者肾性贫血的疗效分析[J].现代诊断与治疗,2022,33(12):1769-1771.[15]刘莹莹,刘磊,李祖海,等.罗沙司他治疗老年维持性血液透析患者肾性贫血的疗效和安全性[J].安徽医学,2022,43(7):747-752.[16]孙艳玲,谢华,康喆,等.罗沙司他治疗初始血液透析患者肾性贫血20例疗效研究[J].中国实用内科杂志,2020,40(11):942-946.[17]孙凌霜,薛瑾虹,魏萌,等.罗沙司他替代大剂量重组人红细胞生成素治疗维持性血液透析患者贫血的疗效[J].肾脏病与透析肾移植杂志,2021,30(3):217-221.[18]张艳艳,蔡虹.罗沙司他对维持性血液透析肾性贫血患者的疗效[J].菏泽医学专科学校学报,2022,34(3):36-39.[19]董建华,范文静,吴边,等.罗沙司他治疗血液透析患者红细胞生成素低反应性贫血的疗效观察[J].肾脏病与透析肾移植杂志,2021,30(3):211-216.[20]方蕾,黄扬扬,伍学琪.罗沙司他与重组人促红素治疗维持性血液透析患者肾性贫血的效果[J].中国医药导报,2021,18(11):137-140.

相似文献/References:

[1]于代华.Hcy对重组人促红素改善急性脑梗死患者认知功能障碍的影响[J].医学信息,2020,33(19):59.[doi:10.3969/j.issn.1006-1959.2020.19.018]
 YU Dai-hua.Effect of Hcy on Recombinant Human Erythropoietin to Improve Cognitive Dysfunction in Patients with Acute Cerebral Infarction[J].Journal of Medical Information,2020,33(16):59.[doi:10.3969/j.issn.1006-1959.2020.19.018]

更新日期/Last Update: 1900-01-01